UARK 2010-35, A Phase II Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma.
Phase of Trial: Phase II
Latest Information Update: 20 May 2017
At a glance
- Drugs Bortezomib (Primary) ; Natural killer cell therapy (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 12 Jan 2017 Status changed from recruiting to completed.
- 06 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 06 Oct 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.